Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
20 sept. 2023 04h30 HE
|
Alvotech
REYKJAVIK, Iceland, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
18 sept. 2023 06h00 HE
|
AiViva Biopharma
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
BetterLife Pharma to Host Investors Update Call on September 18, 2023
14 sept. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
12 sept. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Announces Changes to the Leadership Team
05 sept. 2023 09h30 HE
|
Alvotech
REYKJAVIK, Iceland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
05 sept. 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
30 août 2023 16h15 HE
|
Alvotech
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s...
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
22 août 2023 09h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...